In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
FAQs
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Reimbursement

Hospital to Outpatient Spillover: Concepts and Measurement of Pharmaceutical Pull-Through

Executive Summary

Drug marketers readily accept the concept of spillover in managed care contracting--the idea that drugs mandated by MCO contract can influence other physician prescribing decisions. The spillover effect can be seen as patients move from inpatient to outpatient treatment.

You may also be interested in...



US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques

The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.

Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease

Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.

Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.

Table

View full table

Topics

Tags:
BioPharmaceutical Reimbursement
UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By